Marco Smit Email & Phone Number

California, United States

San Francisco Bay Area

Gesund.ai was selected to the CB Insights AI 100 and the first cohort of the CancerX Accelerator in 2024. I lead commercial growth and partnership development for Gesund.ai, the leader in testing & evaluation technology for medical AI. Combining proprietary AI-native technology with partner networks to deliver 'Easy Button' for FDA clearances & approval for clinical AI. Pivoted company to grow more among pharmaceutical and medical device customers , which has ignited growth.Leadership role in engagement with FDA, HHS, CHAI, and others. Founding member of two CHAI working groups (Assurance Labs, Pharmaceutical and Medical Devices).

San Francisco Bay Area

Recruited to advance Caresyntax's transition from innovation in IoT to SaaS to RWD/RWE. Reported to CEO. P&L responsibility. Joined portfolio management committee. Set up new payor business unit. Leadership role in key partnerships. Refocused global new real-world data (RWD) and AI initiatives from long-term R&D to product development and commercialization as well.

Palo Alto, Ca

As a mentor in Stanford’s StartX (Med) Startup Accelerator, and UCSF, I help entrepreneurs and leadership teams of young insurtech, healthtech, AI, and data/RWE companies to address different growth hurdles. Hurdles can be related to product management, business development, cross-functional team leadership, attracting talent, pricing / business model innovation and of course fundraising.

San Francisco Bay Area

Leading partnership and M&A opportunities for (real world) data, technology, and broader scaling acceleration. Leadership role in Roche's fast-growing business unit that is pioneering a whole new SaaS platform for clinical decision AI that supports providers and patients. Driving negotiations and leading data and real-world evidence partnerships and multiple M&A projects in the US and Europe. Aligning internal and external stakeholders - across functions, geographies, and seniority levels - to galvanize support for the projects to be successful pre- and post-deal signing.Leadership roles in multiple organizational change initiatives and strategic growth programs.Building out ecosystem of technology partners, including companies, institutions, startups and incubator programs in the US and abroad (incl. Israel).

Sunnyvale, Ca

Now part of Fidelity Netbenefits. HealthExpense pioneered an innovative, integrated B2B2C data (SaaS) and payments (%) platform for consumer healthcare payments. Resolved complex data challenges and used an 'AI-light' engagement model to improve patient engagement 10x over industry baseline. Ignited growth to exceed 30% (monthly) soon after becoming CEO. Pivoted company away from low margin/low growth business to HSA market, which was high growth/high margin.Chief Executive Officer 2016-2018.Chief Commercial Officer 2014-2015.

Greater San Diego Area

LynxBio is a pioneer in precision medicine with an initial focus on oncology. Its innovative technology platform has the potential to revolutionize the use of chemotherapy, as well as how oncologists make choices among many similar chemotherapy options.

San Francisco Bay Area

Clients: Fortune 500 companies, investors, and startups in healthcare innovation. For incumbents (pharma, payers, providers, software): Identify startups to invest/acquire/partner with. Develop business plans - or make strategies actionable on P&L and product level - for technology or media companies entering health markets.For startups: improving marketing/product/sales, devise business model changes, accelerate scaling, establish pilots or partnerships with right organization (pharma, insurers, tech companies entering health markets, etc.).Multiple acquisitions, pilots, partnerships or funding.Frequent speaker at conferences and corporate innovation acceleration events.

San Francisco Bay Area

I started Health 2.0 Advisors, as Health 2.0's Innovation Analytics & Acceleration business unit. Clients included Fortune 500 companies (high tech, consumer, enterprise, big pharma) such as Roche, Genentech, Xerox ACS, Abbvie, First Databank, Plantronics, Eli Lilly, and UCB.Government and non-profit clients included the White House’s healthcare innovation leadership team (ONC/HIT), Gordon and Betty Moore Foundation, and Packard Foundation. Also worked with dozens of startups (data analytics, fintech, insurance, benefits, payments, etc.) with game changer potential. Acquired by HIMSS.org.

Santa Clara, Ca

Affymetrix (NASDAQ:AFFX) invented the biochip and was the biochip market leader in genetics and genomics research. Acquired by Thermo Fisher Scientific for $1.3 Billion.Led multiple product and market development initiatives, incl. clinical market development in the US and Europe, new product development in cancer and pre-natal diagnostics, and was member of several task forces (e.g. Affy Labs, which was later acquired by Navigenics).

Spectral Genomics revolutionized the field of cytogenetics and first-of-its-kind patient stratification capabilities to the HEM/ONC (cancer) diagnostics market, becoming the gold standard in $7.4 bil maternal and prenatal diagnostics market.Developed and executed differentiated product strategy and restructured manufacturing operations for better scaling, and build a portfolio of strategic partnerships.Structured and negotiated portfolio of >20 partnerships and licenses (technology, products, distribution, etc.) with Affymetrix, Genzyme Genetics, and Labcorp. Negotiated pivotal licenses for diagnostics and research markets with Affymetrix that enabled SG to raise $9.3 Million in Series B funding.

Monitor Company was founded by Michael Porter and other HBS professors and had become global strategy and investment services consulting firm with over 1,000 consultants and 30 offices worldwide. Cambridge, MA, Los Angeles, and Hong Kong-Asia offices.Worked closely with leadership teams of technology, mobile/telco, banks, info services, and pharmaceutical companies to uncover/anticipate and deliver strong new growth (revenue, profits) in new and existing markets. Clients include Genentech (Rituxan), AT&T, China Trust Bank, Essilor, Thomson Reuters, and World Bank.

Global management consulting firm of $1 Billion in 2005, acquired and later divested by EDS. Worked out of Benelux office and for European CEO (London). Sold $7 mil consulting project in first year.